On November 16, DUALITYBIO-B fell 4.55% in Regular Trading to HK$97.55, with turnover of HK$27.47 million.
The clearest disclosed catalyst is that recent chairman on-market purchases and company buybacks have provided limited near-term support, while the stock has fallen below the chairman’s recent accumulation range.
Recent filings show Chairman Zhu Zhongyuan bought 10,000 shares on November 10 at an average HK$107.276, lifting his stake to 17.66%. Before that, he made multiple on-market purchases from late October through November 6, including 30,000-share buys at HK$104.765, HK$108.7487, HK$105.3923, HK$103.423 and HK$101.2425. The company also repurchased shares on November 2, 3, 5 and 6. Together, these actions signaled longer-term confidence, but the latest movement alert indicated they were insufficient to support the price intraday as the market continued digesting earlier clinical-result-related pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments